Search results
Results From The WOW.Com Content Network
A sestamibi parathyroid scan is a procedure in nuclear medicine which is performed to localize parathyroid adenoma, which causes Hyperparathyroidism. [1] Adequate localization of parathyroid adenoma allows the surgeon to use a minimally invasive surgical approach.
Technetium (99m Tc) sestamibi (commonly sestamibi; USP: technetium Tc 99m sestamibi; trade name Cardiolite) is a pharmaceutical agent used in nuclear medicine imaging. The drug is a coordination complex consisting of the radioisotope technetium-99m bound to six (sesta=6) methoxyisobutylisonitrile (MIBI) ligands. The anion is not defined.
Hyperparathyroidism is confirmed by blood tests such as calcium and PTH levels. A specific test for parathyroid adenoma is sestamibi parathyroid scintigraphy, often referred to as sestamibi scan or, more colloquially, MIBI scan. This nuclear imaging technique reveals the presence and location of pathological parathyroid tissue. [7]
Nuclear medicine imaging methods are used by surgeons to locate which parathyroid gland is responsible for hyperparathyroidism or to find ectopic parathyroid adenomas, most commonly found in the anterior mediastinum. [citation needed] Historically, technetium sestamibi scintigraphy was the main method used or this indication. [39]
A nuclear pharmacist adds anywhere from 50 - 100 mCi of Na[99m TcO 4] to the reaction vial to make the final product, in the pH range of 3.8 to 8.0. After being allowed to react at room temperature for 15 minutes to ensure maximum labeling of the human albumin with 99m Tc, the kit can then be diluted with sterile normal saline as needed.
Single-photon emission computed tomography (SPECT, or less commonly, SPET) is a nuclear medicine tomographic imaging technique using gamma rays. [1] It is very similar to conventional nuclear medicine planar imaging using a gamma camera (that is, scintigraphy), [2] but is able to provide true 3D information. This information is typically ...
Technetium (99m Tc) exametazime is a radiopharmaceutical sold under the trade name Ceretec, and is used by nuclear medicine physicians for the detection of altered regional cerebral perfusion in stroke [1] and other cerebrovascular diseases.
Dacryoscintigraphy (DSG), also known as lacrimal scintigraphy, is a nuclear medicine technique for imaging the lacrimal apparatus. It is used to identify obstructions, for example in the lacrimal duct, nasal cavity or nasolacrimal duct.